Digitisation | June 16, 2022
CytoSMART introduces ML algorithm for organoid analysis
The innovative software module is designed to meet growing scientific demand from researchers and drug developers
The innovative software module is designed to meet growing scientific demand from researchers and drug developers
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Bayer now present in four of the largest biotechnology hubs in the United States
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Subscribe To Our Newsletter & Stay Updated
